MedTrace Logo

Optimal Duration of Olanzapine Add-on Therapy in Major Depression

NCT00568672 · Status: WITHDRAWN · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2023-02-09

No results posted yet for this study

Summary

Evaluation of olanzapine versus placebo in the continuation therapy of subjects with major depression who had a response with additional olanzapine to an antidepressant.

Conditions

  • Relapse Rate of a Major Depressive Episode
  • Safety of Olanzapine in Subjects With Major Depression

Interventions

DRUG

Olanzapine

Olanzapine 5 mg / day for 6 months

Sponsors & Collaborators

Principal Investigators

  • Ion Anghelescu, MD · Charité - University Berlin, Campus Benjamin Franklin, Department of Psychiatry and Psychotherapy

  • Arnim Quante, MD · Charite, University Berlin, Campus Benjamin Franklin, Department of Psychiatry and Psychotherapy

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-10-31
Primary Completion
2008-01-31
Completion
2008-04-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00568672 on ClinicalTrials.gov